Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: An observational study

Lancet

Volumn 361, Issue 9363, 2003, Pages 1077-1083

  Anker, Stefan D ^a,b   Negassa, Abdissa ^c   Coats, Andrew J S ^b   Afzal, Rizwan ^c   Poole Wilson, Philip A ^b   Cohn, Jay N ^d   Yusuf, Salim ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

ADULT; AGE; AGED; ARTICLE; CACHEXIA; EDEMA; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK; SEX DIFFERENCE; SURVIVAL; WEIGHT REDUCTION;

EID: 0037471843     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12892-9     Document Type: Article

References (32)

1. Anker S.D., Ponikowski P., Varney S., et al. Wasting as independent risk factor of survival in chronic heart failure. Lancet. 349:1997;1050-1053.
2. Hornig B., Arakawa N., Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J. 19:(suppl G):1998;48-53.
3. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 82:1990;1730-1736.
4. Francis G.S., Cohn J.N., Johnson G., Rector T.S., Goldman S., Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation. 87:(suppl VI):1993;VI40-VI48.
5. Anker S.D., Chua T.P., Swan J.W., et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure: The importance for cardiac cachexia. Circulation. 96:1997;526-534.
6. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
7. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
8. Anker S.D., Ponikowski P.P., Clark A.L., et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 20:1999;683-693.
9. Florea V.G., Henein M.Y., Rauchhaus M., et al. The cardiac component of cardiac cachexia. Am Heart J. 144:2002;45-50.
10. Anker S.D., Sharma R. The syndrome of cardiac cachexia. Int J Cardiol. 85:2002;51-66.
11. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:1990;236-241.
12. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation. 103:2001;2055-2059.
13. Rauchhaus M., Doehner W., Francis D.P., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 102:2000;3060-3067.
14. Anker S.D., Coats A.J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 86:2002;123-130.
15. Anker S.D., Volterrani M., Pflaum C.-D., et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol. 38:2001;443-452.
16. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 20:1992;248-254.
17. Witte K.K., Clark A.L. Nutritional abnormalities contributing to cachexia in chronic illness. Int J Cardiol. 85:2002;23-31.
18. Poehlmann E.T., Scheffers J., Gottlieb S.S., Fisher M.L., Vaitekevicius P. Increased resting metabolic rate in patients with congestive heart failure. Ann Intern Med. 121:1994;860-862.
19. Anker S.D., Swan J.W., Volterrani M., et al. The influence of muscle mass, strength, fatiguability, and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J. 18:1997;259-269.
20. Doehner W., Rauchhaus M., Florea V.G., et al. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J. 141:2001;792-799.
21. Sharma R., Anker S.D. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol. 85:2002;161-171.
22. Anker S.D., Egerer K., Volk H.-D., Kox W.J., Poole-Wilson P.A., Coats A.J.S. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol. 79:1997;1426-1430.
23. Niebauer J., Volk H.-D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 353:1999;1838-1842.
24. Eriksson S.V., Kjekshus J., Eneroth P., Swedberg K. Neopterin, tumor necrosis factor, c-reactive protein and prostaglandin E2 in patients with severe congestive heart failure treated with enalapril. Circulation. 96:(suppl):1997;I-322. abstr.
25. Gennari R., Alexander J.W., Boyce S.T., Lilly N., Babcock G.F., Cornaggia M. Effects of the angiotensin converting enzyme inhibitor enalapril on bacterial translocation after thermal injury and bacterial challenge. Shock. 6:1996;95-100.
26. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 355:2000;1582-1587.
27. Anker S.D., Davos C.H., Francis D., et al. Body mass index, obesity, and cachexia vssurvival in chronic heart failure-results from the ELITE 2 study. J Am Coll Cardiol. 37:(suppl):2001;203. abstr.
28. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 344:2001;1651-1658.
29. Coats A.J.S., Anker S.D., Roecker E.B., et al. Prevention and reversal of cardiac cachexia in patients with severe heart failure by carvedilol: results of the COPERNICUS study. Circulation. 104:(suppl):2001;II-437. abstr.
30. Clark A.L., Loebe M., Potapov E., et al. Ventricular assist device in severe heart failure. Effects on cytokines, complement and body weight. Eur Heart J. 22:2001;2275-2283.
31. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., Woo M.A., Tillisch J.H. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 38:2001;789-795.
32. Davos C.H., Doehner W., Rauchhaus M., et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail. 9:2003;29-35.